CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

What if you could follow up your workout at the gym with a concierge physician consult to reach your fitness goals? AT Dallas ...

However, the rising popularity of GLP-1 drugs, which are highly effective in helping people lose weight and also reduce the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

The Princeton-based startup said the move was related to “a revenue mix shift within the Noom business" driven by a change in ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.